Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation

PHASE3CompletedINTERVENTIONAL
Enrollment

1,604

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

December 1, 2021

Study Completion Date

November 1, 2022

Conditions
Trauma Injury
Interventions
BIOLOGICAL

Cryoprecipitate

Cryoprecipitate is a blood product high in fibrinogen. The Cryoprecipitate will be given with 90 minutes of emergency department arrival. Cryoprecipitate dose will be 3 pools (equivalent to 15 single units).

BIOLOGICAL

Red Blood Cells

RBCs are utilized as part of the Massive Transfusion protocol for hemorrhage control.

BIOLOGICAL

Plasma

Plasma is utilized as part of the Massive Transfusion protocol for hemorrhage control.

BIOLOGICAL

Platelets

Platelets are utilized as part of the Massive Transfusion protocol for hemorrhage control.

BIOLOGICAL

Whole Blood

Whole Blood is utilized as part of the Massive Transfusion protocol for hemorrhage control.

Trial Locations (25)

77030

The University of Texas Health Science Center at Houston, Houston

B15 2TH

Queen Elizabeth Hospital, Birmingham

BN2N 5BE

Royal Sussex County Hospital, Brighton

BS10 5NB

Southmead Hospital, Bristol

CB2 0QQ

Addenbrooke's Hospital, Cambridge

CF14 4XW

University Hospital of Wales, Cardiff

CV2 2DX

University Hospital of Coventry and Warwickshire, Coventry

HU3 2JZ

Hull Royal Infirmary, Hull

LS1 3EX

Leeds General Infirmary, Leeds

L9 7AL

University Hospital Aintree, Liverpool

E1 1BB

Royal London Hospital, London

SE5 9RS

King's College Hospital, London

SW17 0QT

St. George's Hospital, London

W2 1NY

St. Mary's Hospital, London

M13 9WL

Manchester Royal Infirmary, Manchester

M6 8HD

Salford Royal Hospital, Manchester

TS4 3BW

James Cook University Hospital, Middlesbrough

NE1 4LP

Royal Victoria Infirmary, Newcastle upon Tyne

NG7 2UH

Queens Medical Centre, Nottingham

OX3 9UD

John Radcliffe Hospital, Oxford

PL6 8DH

Derriford Hospital, Plymouth

PR2 9HT

Royal Preston Hospital, Preston

S5 7AU

Northern General Hospital, Sheffield

SO16 6YD

University Hospital Southampton, Southampton

ST4 6QG

University Hospital of North Staffordshire, Stoke-on-Trent

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Queen Mary University of London

OTHER

collaborator

NHS Blood and Transplant

OTHER_GOV

lead

Bryan Cotton

OTHER

NCT04704869 - Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation | Biotech Hunter | Biotech Hunter